APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL)

Stopped Sponsor decision

Conditions

• Non Hodgkin Lymphoma
• Chronic Lymphocytic Leukemia
• Mantle Cell Lymphoma

Interventions

• DRUG: APR-246 (eprenetapopt) + Acalabrutinib in CLL
• DRUG: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in CLL
• DRUG: APR-246 (eprenetapopt) 4.5 g/d + (Acalabrutinib, OR, (Venetoclax +Rituximab)), in CLL and/or MCL and/or RT
• DRUG: APR-246 (eprenetapopt) 4.5 g/d + Venetoclax + Rituximab in RT

Sponsor

Aprea Therapeutics